source
- Merck projects continued investment and growth as Keytruda patent expiresMerck reported third‑quarter results on an investor call, saying sales expectations were above forecasts thanks to strong performance of subcutaneous Keytruda and the pulmonary arterial hypertensio…
- Dren Bio raises $350 million to advance rare blood cancer antibodyDren Bio, a California biotech, announced a $350 million financing round to fund late‑stage development and commercial preparation of its lead therapy, a CD94‑targeting monoclonal antibody known as…